[1].Killick, E., et al., Role of Engrailed–2 (EN2) as a prostate cancer detection biomarker in genetically high risk men.Sci Rep, 2013. 3: p. 2059.
[2].Zhou, Y. J., et al., Down-regulation of miR–605 promotes the proliferation and invasion of prostate cancer cells by up-regulating EN2. Life Sci, 2017. 190: p. 7–14.
[3].Zhou, Y., et al., The biological functions and mechanism of miR212 in prostate cancer proliferation, migration and invasion via targeting Engrailed–2. Oncol Rep, 2017. 38(3): p. 1411–1419.
[4].Morgan, R., et al., Engrailed–2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer. Clin Cancer Res, 2011. 17(5): p. 1090–8.
[5].Andriole, G. L., et al., Mortality results from a randomized prostate-cancer screening trial. N Engl J Med, 2009. 360(13): p. 1310–9.
[6].Dai, X., et al., Benign Prostatic Hyperplasia and the Risk of Prostate Cancer and Bladder Cancer: A Meta-Analysis of Observational Studies. Medicine (Baltimore), 2016. 95(18): p. e3493.
[7].Zhang, L., et al., Autophagy: a stumbling block of androgen inhibition to treat benign prostatic hyperplasia or prostate cancer. Asian J Androl, 2016. 18(4): p. 654–6.
[8].Morgan, R., et al., Targeting HOX/PBX dimers in cancer. Oncotarget, 2017. 8(19): p. 32322–32331.
[9].Lai, C. Y., et al., Engrailed–2 might play an anti-oncogenic role in clear-cell renal cell carcinoma. J MolHistol, 2016. 47(3): p. 229–37.
[10].Bose SK, Bullard RS, Donald CD: Oncogenic role of engrailed–2 (en–2) in prostate cancer cell growth and survival. Transl Oncogenomics 2008, 3: p.37–43.
[11].Pandha, H., et al., Urinary engrailed–2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer. BJU Int, 2012. 110(6 Pt B): p. E287–92.
[12].Carlier, L., et al., Investigation of homeodomain membrane translocation properties: insights from the structure determination of engrailed–2 homeodomain in aqueous and membrane-mimetic environments. Biophys J, 2013. 105(3): p. 667–78.
[13].Watanabe, A., et al., Absolute Neutrophil Count Predicts Postoperative Prognosis in Mass-forming Intrahepatic Cholangiocarcinoma. Anticancer Res, 2019. 39(2): p. 941–947.
[14].Kim, J. and J. S. Bae, Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment. Mediators Inflamm, 2016. 2016: p. 6058147.
[15].Kim, J. and J. S. Bae, Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment. Mediators Inflamm, 2016. 2016: p. 6058147.
[16].Zhang, L., et al., Autophagy: a stumbling block of androgen inhibition to treat benign prostatic hyperplasia or prostate cancer. Asian J Androl, 2016. 18(4): p. 654–6.
[17].Dai, X., et al., Benign Prostatic Hyperplasia and the Risk of Prostate Cancer and Bladder Cancer: A Meta-Analysis of Observational Studies. Medicine (Baltimore), 2016. 95(18): p. e3493.
[18].Joliot, A., et al., Identification of a signal sequence necessary for the unconventional secretion of Engrailed homeoprotein. CurrBiol, 1998. 8(15): p. 856–63.
[19].Logan, C., et al., Cloning and sequence comparison of the mouse, human, and chicken engrailed genes reveal potential functional domains and regulatory regions. Dev Genet, 1992. 13(5): p. 345–58.
[20].Li Q, Lu S, Li X, Hou G, Yan L, Zhang W, Qiao B: Biological function and mechanism of miR–33a in prostate cancer survival and metastasis: via downregulating Engrailed–2. CLIN TRANSL ONCOL 2017, 19(5): p.562–570.
[21].Rosa M, Dondossola ER, Alexandre M, Madeira K, Cardoso FA, Grande AJ: Urinary EN–2 to predict prostate cancer: Systematic review and meta-analysis. Rev Assoc Med Bras (1992) 2017, 63(7): p. 656–661.
[22].McGrath, S. E., et al., Engrailed–2 (EN2) - a novel biomarker in epithelial ovarian cancer. BMC Cancer, 2018. 18(1): p. 943.
[23]. Natasha punia, Monika primon, Guy R. simpson1, Hardev s. pandha1, Richard Morgan, Membrane insertion and secretion of the Engrailed–2 (EN2) transcription factor by prostate cancer cells may induce antiviral activity in the stroma. Sci Rep. 2019. 26;9(1): p. 5138.
[24]. Eugenia Scaccianoce, et al., Characterization of Prostate Cancer DU145 Cells Expressing the Recombinant Androgen Receptor. Oncology Research, 2003. 14,:p. 101–112.
[25]. Saleh Altuwaijri, et al., Expression of human AR cDNA driven by its own promoter results in mild promotion, but not suppression, of growth in human prostate cancer PC–3 cells. Asian J Androl, 2007. 9 (2): p.181–188.
[26]. Jin Li, et al.,SHARPIN overexpression induces tumorigenesis in human prostate cancer LNCaP, DU145 and PC–3 cells via NF-jB/ERK/Akt signaling pathway. Med Oncol, 2015. 32(1).
[27].Andriole, G. L., et al., Mortality results from a randomized prostate-cancer screening trial. N Engl J Med, 2009. 360(13): p. 1310–9.